Biostem Technologies

Biostem Technologies Market capitalization

The The market capitalization of Biostem Technologies (BSEM) as of Nov 19, 2026 is 94.76 M USD. In the previous year, The market capitalization was 94.76 M USD — a change of 0.00% (lower).

Market capitalization

94.76 MUSD

YoY

0.00%

Last updated:

In 2024, Biostem Technologies's market cap stood at 94.76 M USD, a 0.00% increase from the 94.76 M USD market cap in the previous year.

The Biostem Technologies Market capitalization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Market capitalization
Date
Market capitalization
Jan 1, 2017
94.76 M USD
Jan 1, 2018
94.76 M USD
Jan 1, 2019
94.76 M USD
Jan 1, 2020
94.76 M USD
Jan 1, 2021
94.76 M USD
Jan 1, 2022
94.76 M USD
Jan 1, 2023
94.76 M USD
Jan 1, 2024
94.76 M USD
The Biostem Technologies Market capitalization history
YEARMarket capitalizationYoY
94.76 MUSD0.00%
94.76 MUSD0.00%
94.76 MUSD0.00%
94.76 MUSD0.00%
94.76 MUSD0.00%
94.76 MUSD0.00%
94.76 MUSD0.00%
94.76 MUSD0.00%
94.76 MUSD0.00%
94.76 MUSD0.00%
94.76 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biostem Technologies Stock analysis

What does Biostem Technologies do? Biostem Technologies Inc is a US company specializing in regenerative medicine. It was founded in 2007 and is based in Clearwater, Florida. Biostem Technologies is listed on the OTCQB Stock Exchange and offers a wide range of products in the field of regenerative medicine. The company's business model primarily involves advancing growth in the field of regenerative medicine through the development and marketing of new products and technologies. They focus on the production of stem cells that can be used in the regeneration of damaged tissues and organs. They also offer research and development of stem cell therapies, manufacturing of stem cell products, and related services. Biostem Technologies places emphasis on processing umbilical cord blood stem cells, collaborating with medical facilities to collect and isolate these cells for preservation. The company has also developed products such as BioStem Serum and BioStem Gel, made from stem cells and used in regeneration and wound healing. They have developed technologies for regenerating damaged tissues and organs, including a technology for regenerating muscle and adipose tissue through stem cell injection. Clinical studies have shown promising results with this technology. Biostem Technologies has partnerships with other companies and institutes in the field of regenerative medicine, including working with the National Institute of Neurological Disorders and Stroke to develop a new therapy for multiple sclerosis. They also provide consulting services to assist other companies in developing regenerative products and services. In conclusion, Biostem Technologies is a leading company in the field of regenerative medicine and stem cell therapies, offering a range of products and services. They also provide important technologies for tissue regeneration, positioning them as a key player in the field of regenerative medicine. Biostem Technologies is one of the most popular companies on Eulerpool.

Market capitalization Details

Exploring Biostem Technologies's Market Capitalization

Biostem Technologies's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Biostem Technologies's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Biostem Technologies's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Biostem Technologies’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Biostem Technologies stock

The market capitalization of Biostem Technologies is 94.76 M USD in 2024.

The market capitalization of Biostem Technologies changed from 94.76 M USD to 94.76 M USD, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The market capitalization Biostem Technologies since 2006 – with annual values, charts, and detailed analysis.

Market capitalization (German: Market capitalization, English: market capitalisation or market cap) is the calculated total value of all shares of a publicly traded company. The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company. It is determined by the supply and demand for the company's shares. Thus, market capitalization is significantly influenced by expectations in the stock market regarding the future earnings power of the company and, therefore, can be subject to significant fluctuations.

Number of shares * share price = market capitalization

To evaluate The market capitalization's USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for The market capitalization.

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare The market capitalization's Biostem Technologies with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Biostem Technologies

All Key Metrics — Biostem Technologies